Breast Cancer
Conference Coverage
Endocrine therapy benefits in premenopausal breast cancer differ by molecular risk
News
Evolving strategies in sequencing for HER2+ MBC therapy
In a 12-month window, the FDA approved four agents targeting HER2-positive MBC.
News
New targeted treatments are major advances for HER2-positive breast cancer
Conference Coverage
GELATO trial: Chemoimmunotherapy may help in metastatic invasive lobular breast cancer
Conference Coverage
No survival dip with neoadjuvant letrozole-palbociclib in NeoPAL study
Conference Coverage
BERENICE: Further evidence of heart safety of dual HER2 blockade
Clinical Topics & News
Screening High-Risk Women Veterans for Breast Cancer
Women at high-risk for developing breast cancer at 2 urban Veterans Affairs medical centers with large minority populations and high-levels of...
Conference Coverage
Breast cancer survivors have specific gynecological needs
The side effects of breast cancer treatments, particularly for those with HR-positive breast cancer, means that patients and survivors have...
Article
The power and promise of social media in oncology
Dr. Alan Lyss describes a recent presentation on the role of social media in oncology.
Article
Hyperprogression on immunotherapy: When outcomes are much worse